Jury awards Nektar $90 million in lawsuit against Eli Lilly over licensing dispute

A federal jury in a US District Court awarded Nektar Therapeutics $90 million after finding Eli Lilly breached a licensing agreement.

The verdict ends a dispute that began when the parties' licensing deal fell apart, with Nektar originally seeking a larger sum.

While the award is a win for the biotech, the amount is far below what Nektar had pursued, limiting its overall financial impact.